Search Results for: "traditional cost-effectiveness"

–Special considerations include patient age, benefit durability, and rarity of condition–  –Report will be subject to public deliberation at January 25th Midwest CEPAC meeting– BOSTON, January 12, 2018 – The Institute for Clinical and Economic Review (ICER) today released its revised Evidence Report assessing the comparative clinical effectiveness and value of voretigene neparvovec (LuxturnaTM, Spark Therapeutics) for treatment of vision […]

Objectives: To evaluate alternative methods to calculate and/or attribute economic surplus in the cost-effectiveness analysis ofsingle or short-term therapies.Methods: We performed a systematic literature review of articles describing alternative methods for cost-effectivenessanalysis of potentially curative therapies whose assessment using traditional methods may suggest unaffordablevaluations owing to the magnitude of estimated long-term quality-adjusted life-year (QALY) gains […]

Cost-Effectiveness, the QALY, and the evLYG Clinicians play a vital role in helping individual patients decide what treatment is best for them. In contrast, cost-effectiveness analysis looks at evidence for entire patient populations, comparing the health benefits and economic costs of different treatment options. The goal of cost-effectiveness analysis is to help inform policy so that treatments that […]

— Analysis has been commissioned by the U.S. Department of Veterans Affairs to help evaluate data from a completed clinical trial comparing patient outcomes with specially trained service dogs to outcomes with emotional support dogs without specialized training — — The final ICER report will be submitted to the National Academy of Medicine for deliberation […]

— As with all treatments for ultra-rare conditions, judgments of overall value require consideration of the broader patient benefits and contextual issues that will be discussed at the October 25 public meeting — BOSTON, October 11, 2018 – The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value […]

Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit for iptacopan over C5 inhibitor; committee voted that the evidence is adequate to demonstrate a net health benefit for add-on danicopan compared to C5 inhibitor alone

Iptacopan and danicopan are two first-in-class agents that provide important health benefits, but there are uncertainties regarding long-term efficacy and safety.

Informed by expert Advisory Group and input from external stakeholders, White Paper highlights ongoing need to develop and test new methods for HTA groups in the US and internationally.

Public comment period now open until February 2, 2023; Requests to make oral comment during public meeting also being accepted

Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties.